Zobrazeno 1 - 10 of 79 pro vyhledávání: '"Minehiko, Inomata"'
1
Akademický článek
An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma
Autor: Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizusihima, Kenji Azechi, Naoki Takata, Nozomu Murayama, Kana Hayashi, Takahiro Hirai, Zenta Seto, Kotaro Tokui, Yasuaki Masaki, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Hirokazu Taniguchi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Minehiko Inomata
Publikováno v: Discover Oncology, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract Background Pulmonary sarcomatoid carcinoma is a rare tumor that is resistant to cytotoxic agents. This observational study aimed to evaluate the detection rate of driver gene alteration and the efficacy of targeted therapy for pulmonary sarc
Externí odkaz: https://doaj.org/article/0daef32daf774bb8b141fae7e8643c1d
Zobrazit plný text záznamu
2
Akademický článek
Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer
Autor: Minehiko Inomata, Masahiro Matsumoto, Naoki Takata, Kana Hayashi, Zenta Seto, Takahiro Hirai, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Immune checkpoint inhibitors have significantly improved the prognosis in patients with non-small cell lung cancer, compared with cytotoxic agents. However, the prediction of treatment response is often difficult, even after assessing the tu
Externí odkaz: https://doaj.org/article/b0def5af260d4ffb910a8901979993fb
Zobrazit plný text záznamu
3
Akademický článek
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice
Autor: Minehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizushima, Kenji Azechi, Naoki Takata, Nozomu Murayama, Kana Hayashi, Takahiro Hirai, Zenta Seto, Kotaro Tokui, Yasuaki Masaki, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Hirokazu Taniguchi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
Publikováno v: Thoracic Cancer, Vol 14, Iss 17, Pp 1618-1623 (2023)
Abstract Objective Studies have suggested the potential efficacy of immune checkpoint inhibitors (ICIs) for pulmonary sarcomatoid carcinoma. This multicenter observational study was conducted to evaluate the efficacy of systemic ICI therapy and chemo
Externí odkaz: https://doaj.org/article/d017de19d4e6443389f1d93a76555a9a
Zobrazit plný text záznamu
4
Akademický článek
Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
Autor: Minehiko Inomata, Masahiro Matsumoto, Isami Mizushima, Kana Hayashi, Zenta Seto, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
Publikováno v: The Egyptian Journal of Bronchology, Vol 16, Iss 1, Pp 1-7 (2022)
Abstract Purpose We conducted a retrospective analysis of the data of patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to investigate the associations between clinical factors and the overall survival. M
Externí odkaz: https://doaj.org/article/8f2fac69bfef4d0bbfcfa51ee111cb99
Zobrazit plný text záznamu
6
Akademický článek
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
Autor: Hideki Terai, MD, Kenzo Soejima, MD, Asanao Shimokawa, PhD, Hidehito Horinouchi, MD, Junichi Shimizu, MD, Tetsunari Hase, MD, Ryota Kanemaru, MD, Kana Watanabe, MD, Kiichiro Ninomiya, MD, Naoko Aragane, MD, Noriko Yanagitani, MD, Yoshihiko Sakata, MD, Masahiro Seike, MD, Daichi Fujimoto, MD, Masashi Kasajima, MD, Akihito Kubo, MD, Sojiro Kusumoto, MD, Yoshitaka Oyamada, MD, Keiichi Fujiwara, MD, Masahide Mori, MD, Midori Hashimoto, MD, Masato Shingyoji, MD, Masahiro Kodani, MD, Jin Sakamoto, MD, Toshihiko Agatsuma, MD, Kosuke Kashiwabara, MD, Minehiko Inomata, MD, Motoko Tachihara, MD, Kazuhisa Tanaka, MD, Kenji Hayashihara, MD, Nobuyuki Koyama, MD, Kaoru Matsui, MD, Koichi Minato, MD, Daisuke Jingu, MD, Hiroyuki Sakashita, MD, Satoshi Hara, MD, Tomoyuki Naito, MD, Asuka Okada, MD, Masayuki Tanahashi, MD, Yuki Sato, MD, Koichiro Asano, MD, Takayuki Takeda, MD, Kensuke Nakazawa, MD, Toshiyuki Harada, MD, Kazuhiko Shibata, MD, Tatsuo Kato, MD, Etsuo Miyaoka, PhD, Ichiro Yoshino, MD, Akihiko Gemma, MD, Tetsuya Mitsudomi, MD
Publikováno v: JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100404- (2022)
Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirma
Externí odkaz: https://doaj.org/article/67a827674fcd4c4087dafceff77375be
Zobrazit plný text záznamu
10
Akademický článek
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
Autor: Minehiko Inomata, Kenji Azechi, Naoki Takata, Kana Hayashi, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
Publikováno v: Diagnostics, Vol 10, Iss 12, p 1006 (2020)
Background: Among patients with non-small cell lung cancer (NSCLC), we compared the progression-free survival (PFS) and proportion of acquisition of T790M mutation of the epidermal growth receptor gene (EGFR) after first-line treatment with epidermal
Externí odkaz: https://doaj.org/article/445524ef0ddf4c539f188e1e53d494d1
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje